Recent Updates
Recently added Catalysts
TLX Positive Sentiment

Telix at ASCO 2026

Friday, May 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Telix will participate in the 2026 ASCO Annual Meeting in Chicago, presenting key findings from its Phase 3 study of TLX591-Tx for prostate cancer. A late-breaking oral presentation will be delivered by Dr. Pedro Barata, alongside a poster presentation on TLX250-Tx for renal cancer. Both therapies are not yet authorized for marketing.
Price reaction · baseline $9.53 (2026-05-28 close) · hit pre-market · 3 other TLX headline(s) in the window, move may be shared
day 0 close · peak
-1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Telix will present significant findings at ASCO 2026.
  • The late-breaking presentation highlights innovative cancer therapies.
  • Involvement in both prostate and renal cancer studies showcases diverse research.

CONCERNS & RISKS

  • TLX591-Tx and TLX250-Tx have not yet received marketing authorizations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

Telix at ASCO 2026

Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago.
ASCO 2026 will feature a late-breaking oral presentation on safety and dosimetry results from Part 1 of ProstACT Global, Telix’s Phase 3 study of TLX591-Tx ( 177 Lu-rosopatamab tetraxetan) in combination with standard of care versus standard of care alone in patients with PSMA-positive metastatic castration-resistant prostate cancer.
The presentation will be delivered by Pedro Barata, MD, MSc, on Monday, June 1.
Telix’s renal cancer therapeutics program will also be featured at ASCO, with a poster presentation on LUTEON, a Phase 2/3 study evaluating TLX250-Tx ( 177 Lu-girentuximab) in advanced relapsed or recurrent clear cell renal cell carcinoma.
TLX591-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Abstract presentations

June 1, 3:12 PM – 3:24 PM CDT
Arie Crown Theater
May 31, 9:30 AM – 11:30 AM CDT
Hall A (Board 109a)

Frequently Asked Questions

What is the focus of Telix's presentation at ASCO 2026?

Telix will present safety and dosimetry results from its Phase 3 study of TLX591-Tx.

Who will deliver the presentation at ASCO 2026?

Dr. Pedro Barata will deliver the late-breaking oral presentation.

What other study will Telix present at ASCO 2026?

Telix will also feature a poster presentation on TLX250-Tx for renal cancer.

Have TLX591-Tx and TLX250-Tx received marketing authorizations?

No, neither TLX591-Tx nor TLX250-Tx has received marketing authorizations.

ShareAdd on Google
Tags: TLX Viatris Investor Conferences Healthcare TLX591-Tx TLX250-Tx ASCO 2026 prostate cancer renal cancer
Last updated: May 29, 2026

Biotech snapshot

Lead asset
131I-IPAPhase 1
Neoplastic Disease →

Catalyst track record

+13%
best trade around TLX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for TLX.

See every catalyst's timing & PoA →